D. G. Ward et al. (2022) European Urology Oncology, pp.1-9.
Nonacus Products: Cell3 Target: Oncology
There is an unmet need for an accurate, validated, noninvasive test for diagnosing and monitoring bladder cancer (BC). Detection of BC-associated mutations in urinary DNA via targeted deep sequencing could meet this need. The objective was to test the ability of mutational analysis of urinary DNA to noninvasively detect BC within the context of haematuria investigations and non–muscle-invasive BC (NMIBC) surveillance. Capture-based ultra-deep sequencing was performed for 443 somatic mutations in 23 genes in 591 urine cell-pellet DNAs from haematuria clinic patients and 293 from NMIBC surveillance patients. Variant calling was optimised to minimise false positives using urine samples from 162 haematuria clinic patients without BC.